## LH: Labcorp Holdings Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.1% below STRENGTH zone (3.0-6.0%); PEG 1.84 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($250.49)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. A Look At Labcorp (LH) Valuation As Shares Show Mixed Short And Long Term Returns**
- Source: Simply Wall Street | 20260106T053122 | Somewhat-Bullish | Relevance: 100%
- Labcorp Holdings (LH) shows mixed short-term returns but positive longer-term gains, with shares recently closing at $253.18. The company is considered 15.5% undervalued, with a narrative fair value around US$300, driven by anticipated growth from innovative tests and healthier profitability. However, potential risks include tariffs, regulatory changes, and PAMA impacts on Medicare pricing.

**2. Charles River Laboratories: The Quiet Infrastructure Powering the Next Wave of Drug Discovery**
- Source: AD HOC NEWS | 20260105T000231 | Neutral | Relevance: 75%
- Charles River Laboratories has evolved into a comprehensive, end-to-end preclinical R&D and manufacturing platform, serving as the "invisible backbone" for modern drug discovery. The company offers integrated services from target discovery to safety assessment and advanced biologics manufacturing, positioning itself as a critical infrastructure provider for biotechs and pharmas. Its strategic advantages include an end-to-end ecosystem, deep regulatory expertise, early adoption in advanced therapies, and trusted partner status, making it a leveraged play on the health and innovation of the biotech sector.

**3. Maryland Representative April McClain Delaney Purchased as Much as $135,000 in Bio-Techne Shares**
- Source: Bitget | 20260105T230912 | Neutral | Relevance: 60%
- Maryland Representative April McClain Delaney recently purchased between $9,009 and $135,000 worth of Bio-Techne (NASDAQ: TECH) shares on December 2, 2025. This transaction is part of her 147 stock trades over the past three years, totaling over $371,000, and highlights the ongoing requirement for transparency in congressional stock transactions under the STOCK Act. Monitoring such trades can offer insights for investors, though they should not be the sole basis for investment decisions.

**4. Maryland Representative April McClain Delaney Purchased as Much as $135,000 in Bio-Techne Shares**
- Source: Bitget | 20260106T150825 | Neutral | Relevance: 60%
- Maryland Representative April McClain Delaney recently purchased between $9,009 and $135,000 worth of Bio-Techne (NASDAQ: TECH) shares on December 2, 2025. This transaction is part of her extensive trading activity over the past three years, totaling over $371,000 across 147 stock trades. Congressional members are required to disclose such transactions under the STOCK Act, which aims to prevent the use of insider information for personal financial gain.

**5. IDEXX Laboratories: How a Quiet Diagnostics Giant Is Rewriting the Future of Animal Health**
- Source: AD HOC NEWS | 20260104T060839 | Neutral | Relevance: 60%
- IDEXX Laboratories has transformed veterinary diagnostics into a high-margin, high-tech platform business by integrating in-clinic analyzers, reference lab services, software, and AI tools. This ecosystem approach provides a unified workflow for veterinary practices and addresses the rising demand for sophisticated animal healthcare amidst workforce shortages. The company's unique selling proposition lies in its data and AI capabilities, workflow integration, and recurring revenue model, contributing to its strong market valuation and competitive edge against rivals like Zoetis and Antech Diagnostics.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 5 ($3.37M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-0.7%)
- Blackrock Inc.: 9.8% (-10.3%)
- State Street Corpora: 4.6% (-0.8%)
- Victory Capital Mana: 3.2% (+20.0%)
- JPMORGAN CHASE & CO: 2.6% (+64.8%)

### Key Risks

1. Insider selling cluster: $3.4M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +3.0% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.84 elevated, pricing in significant growth expectations. Forward P/E 14.9x stretched relative to 7% growth. Insider selling cluster ($3.4M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $21.6B |
| Beta | 0.97 |
| 52W Range | $209.38 - $293.72 |
| Short Interest | 5.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.84 |
| Forward P/E | 14.9 |
| Current P/E | 15.9 |
| YoY Growth | 7.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -0.8% to 2.1% (+3.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.9pp (needs >3.0% for momentum thesis). MRS_5 at 1.8% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 55. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.14% (CS: 63) | Neutral |
| RSI_14 | 54.6 | Neutral |
| MACD Histogram | 0.45 | Bullish |
| vs SMA20 | 1.015x | Above |
| vs SMA50 | 1.002x | Above |
| vs SMA200 | 1.008x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $260.35
- **Stop Loss:** $250.49 (3.8% risk)
- **Target:** $270.21 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 133
- **Position Value:** $34,626.55
- **Portfolio %:** 34.63%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-02-05 (Est: $3.94)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.14 | $4.18 | +1.0% |
| 2025Q2 | $4.18 | $4.35 | +4.1% |
| 2025Q1 | $3.73 | $3.84 | +2.8% |
| 2024Q4 | $3.39 | $3.45 | +1.7% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_10*